Centrus shorts hold firm as stock slides 18% in a week

Centrus Energy Corp. is the only NRC-licensed domestic producer of high-assay low-enriched uranium in the United States, and right now it is bearing the full weight of the market's scepticism about whether that unique position translates into near-term value. The stock closed at $109.88 on Tuesday, down 18.2% over the past week and 24.3% over the past month, a slide that has left it lagging every close peer in its uranium peer group.

Short interest has climbed to 34.2% of free float, essentially unchanged from the level reported yesterday but up roughly 13% since early October when position sizes jumped from the mid-5 million share range to nearly 6 million shares short. The FINRA fortnightly settlement pegs days-to-cover at 8.08, meaning shorts would need more than a week of normal trading volume to unwind. The borrow market offers no relief valve: availability has been at 0% for most of the past six weeks, a sustained lockout that means every share in the lending pool is already lent out. Cost to borrow, at around 1%, remains surprisingly cheap given this scarcity, which suggests the shorts already in position have no meaningful additional carrying cost to worry about. The ORTEX short score of 78.7 puts this name in the first percentile of the universe on short positioning, the sharpest bearish signal the data produces. Options positioning has edged more cautious: the put/call ratio has climbed to 0.77, up from a recent low of 0.60 two weeks ago and near its 52-week high of 0.84, though at 0.74 standard deviations above its 20-day mean it has not yet reached extreme territory.

The Street's view on Centrus is internally divided in ways that make the analyst data genuinely interesting rather than routine. HC Wainwright reiterated its Buy rating and $300 target on Wednesday. Needham, which cut its target from $264 to $262 in August and again from $262 to $206 on Tuesday, retains a Buy rating but has now taken $56 off its target in two months. Guggenheim initiated at Buy with a $167 target in early October. Jefferies, which initiated in September, went straight to Hold at $169. JPMorgan and UBS both hold Neutral ratings, with targets of $180 and $185 respectively. The mean target across the coverage group is $230, implying roughly 110% upside from the current price. That gap between target and price is the central tension on this name: bullish ratings dominate, but target cuts have been the direction of travel. The EV/EBITDA multiple has compressed by about 1.7 turns over the past 30 days to 17.4x, and the price-to-book has fallen nearly a full turn in the same period to 2.3x. The ORTEX factor score for 12-month forward earnings growth sits at the 64th percentile, but short-term EPS momentum scores rank only in the 17th percentile over 90 days.

The bull case rests on Centrus's $3.9 billion backlog, its status as the only domestic HALEU supplier, and a $900 million DOE task order backing the Piketon facility scale-up. Bears point to the company's continued reliance on Russian TENEX for more than half its LEU supply through 2027, an incomplete funding path to full commercialisation, and construction risk on a facility that has never been built before at this scale. The $500 million ATM raise completed in September has reduced near-term cash risk but also diluted existing holders. Retail attention around the stock, measured by Wikipedia views and ORTEX page traffic, has risen to 3.6 standard deviations above its own 90-day history, the highest reading in the current window, suggesting the drawdown has drawn a broader audience.

On the ownership register, BlackRock has grown its stake to 11.6% from 7.6% at its prior filing, and Van Eck lifted its position to 8.7% from 6.4%. Bank of Nova Scotia filed an amendment on Monday showing its stake has fallen to 3.46% from 6.91% at the prior filing, crossing below the 5% threshold. No Schedule 13D activist filings are on record. All 13D/G stakes are as last disclosed and holders who fall below 5% may not file again.

Earnings are scheduled for November 6, 16 days away. The two most recent post-results sessions produced a move of roughly +2% and a move of roughly -6% respectively, giving no consistent directional pattern but confirming the stock can move sharply on the print. Whether the gap between analyst targets and the current price narrows on results, or whether target cuts continue to chase the share price lower, is the question the November 6 release will answer first.